Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial
Authors' conclusion
Our pilot data suggest no additional improvement in glycaemic control or BW with LAGB and liraglutide therapy. However, this trial was significantly underpowered to detect a significant change in the primary or secondary outcomes. Further trials are needed to investigate whether GLP-1 agonists, and particularly with more effective weekly agents (i.e. semaglutide or tirzepatide), are of benefit following metabolic surgery.
Study context
- Population
- Adults with T2D and obesity undergoing laparoscopic adjustable gastric banding (LAGB)planned 58
- Participants
- 27 adults
- Comparison
- LAGB with liraglutide 1.8 mg vs LAGB with placebo
- Liraglutiden = 13
- Placebon = 14reference
- Primary endpoint
- Change in HbA1c from randomisation to end of treatment
- Follow-up
- 6 months
Methodological detailspilot, double-blind, placebo-controlled, Trial underpowered: 27 randomised vs planned 58 (80% power to detect 0.6% HbA1c difference)
- Pilot
- Double-blind
- Placebo-controlled
- Trial underpowered: 27 randomised vs planned 58 (80% power to detect 0.6% HbA1c difference)
Primary result
HbA1c
Difference
0.2 mmol/mol
CI −11.3 to 11.6
P = 0.98
Between Liraglutide and Placebo
difference 0.2 mmol/mol (CI −11.3 to 11.6); P = 0.98
As reported in the abstract
Secondary outcomes
| Outcome | Difference (mmol/mol) (CI) | P value | |
|---|---|---|---|
| HbA1c · 12 months (6 months off treatment) | 10.9 (1.1–20.6) | P = 0.032 | |
| −100102030Difference, mmol/mol (linear scale) |
| Outcome | Difference (kg) (CI) | P value | |
|---|---|---|---|
| Body weight · 6 months | 2.0 (−4.2 to 8.1) | P = 0.50 | |
| Body weight · 12 months (6 months off treatment) | 8.2 (1.6–14.9) | P = 0.02 | |
| −1001020Difference, kg (linear scale) |
Safety
- No significant differences in adverse events between groups
Original publication
Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial. Int J Obes (Lond). Published 11 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →